Oragenics, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014; balance-sheet comparisons are to December 31, 2013. Oragenics is a development-stage biotechnology company with commercial oral probiotic products and antibiotic and therapeutic-probiotic programs. Its interim financial statements are unaudited.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Revenue | $214,660 | $176,407; up $38,253 |
| Gross profit / gross margin | $134,900 / approximately 62.8% | $112,458 / approximately 63.8% |
| Research and development | $1,016,464 | $745,395 |
| Selling, general and administrative | $767,394 | $1,103,187 |
| Operating loss | $(1,648,958) | $(1,736,124) |
| Net loss | $(1,640,884) | $(1,589,960) |
| Net loss per share, basic and diluted | $(0.05) | $(0.06) |
| Operating cash used | $(1,584,248) | $(1,580,901) |
- Cash and cash equivalents were $14.64 million at March 31, down from $16.28 million at year-end. Cash decreased by $1.64 million during the quarter.
- Working capital was $14.16 million, versus $15.81 million at December 31. Total assets were $15.14 million and shareholders’ equity was $14.20 million.
- Current liabilities totaled $938,102, including $80,326 in short-term insurance-premium notes. The filing reports no material long-term debt balance.
- Accumulated deficit was $71.80 million. Management said existing cash was expected to fund the business as then structured through March 2015, but additional capital would be needed for longer-term plans; no financing source was committed.
Changes and operating developments
- Revenue increased 21.7% year over year. Management attributed the increase primarily to higher ProBiora3 revenue, partly offset by lower grant revenue.
- R&D rose 36.4%, primarily reflecting increased costs for the lantibiotic program and compensation; SG&A fell 30.4%, mainly because consulting, marketing, advertising, conference, and travel costs declined.
- Net loss widened by approximately $51,000 despite a smaller operating loss. Q1 2013 included $144,503 of other income related to proceeds from the sale of the company’s interest in a mutual insurer; no comparable transaction occurred in 2014.
- R&D activity focused on MU1140 and related lantibiotic candidates, with preclinical work and manufacturing development planned. Management anticipated FDA pre-IND discussions in the second half of 2014 and an IND filing by the second half of 2015, conditional on progress.
- Management reported that ProBiora3 sales and marketing results had not met expectations and that outside sales-consultant spending was reduced. Two oral-health studies did not support enhanced product claims and were to be discontinued; a pilot study showed no clear statistically significant improvement over the existing format.
- The company had discontinued its SMaRT Replacement Therapy Phase 1b trial because of enrollment difficulties and was seeking partners. In April 2014, LPThera’s CEO became an Oragenics employee; the company had licensed its LPT3-04 weight-loss candidate to LPThera in December 2013.
Outlook, risks, and unusual items
- The company reported recurring losses and negative operating cash flow since inception, limited revenue, and expectations of substantial future losses and R&D spending. Its ability to continue beyond available resources depends on financing, partnerships, sublicensing, or profitable operations; none is assured.
- Potential financing may dilute existing shareholders or carry senior rights. If funding is unavailable, the company may have to delay or curtail development, trials, or commercialization.
- Intrexon collaboration agreements impose future sales/revenue shares and milestone obligations. As of March 31, no disclosed Lantibiotic ECC, Probiotic ECC, or Texas A&M milestones had been achieved. The agreements also include termination and ongoing development obligations.
- UFRF licenses require annual maintenance payments and may require royalties and commercialization payments if products are commercialized. No commercial sales under those licenses had occurred.
- Four key suppliers support the company’s marketed probiotic products. Cash balances exceeded federally insured limits; $14.39 million was uninsured at quarter-end.
- Management concluded disclosure controls were effective, but disclosed a continuing material weakness in segregation of duties because of the company’s small staff. No material legal proceedings were reported.
Important facts for investors to verify
- Whether cash burn, product sales, and actual spending support management’s estimated runway through March 2015, and what financing options are available.
- Progress and timing of MU1140 preclinical testing, manufacturing, FDA discussions, and the proposed IND filing.
- Whether ProBiora3 sales improve after the marketing strategy changes, and whether further clinical work supports commercial claims.
- The scope and timing of Intrexon and license-related costs, milestone payments, and potential dilution from equity issuance or collaboration obligations.
- Whether the segregation-of-duties weakness is remediated and whether cash concentration and supplier dependence change.